PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy.\', \'Gustave Roussy Cancer Campus, Villejuif, France; Département Interdisciplinaire d\'Organisation des Parcours Patients, Gustave Roussy, Villejuif, France.\', \'APHP-Sorbonne Université, Institut Pierre Louis d\'Epidemiologie et de Santé Publique INSERM 1136, Paris, France.\', \'Department of Medical Oncology, Clinique Saint-Jean, Cagnes-sur-Mer, France.\', \'Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.\', \'Predictive biomarkers and novel therapeutic strategies Group, Institut Gustave Roussy, University of Paris Sud, INSERM 981, Université Paris Saclay, Villejuif, France.\', \'Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0923-7534(21)04550-610.1016/j.annonc.2021.10.014
?:hasPublicationType
?:journal
  • Annals of oncology : official journal of the European Society for Medical Oncology
is ?:pmid of
?:pmid
?:pmid
  • 34718117
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all